Led by Shareholder Christopher P. Simpson, Polsinelli recently represented Alloy Therapeutics (Alloy), a biotechnology ecosystem company dedicated to democratizing access to cutting-edge drug discovery technologies, in a multi-target collaboration and license agreement with Biogen to advance the use of Alloy’s AntiClastic™ ASO Platform, an antisense oligonucleotide technology used to support the design and development of therapeutics.

Under the agreement, Biogen will leverage Alloy’s AntiClastic™ ASO platform to support the discovery and development of therapeutics across multiple targets.

This transaction highlights the growing importance of platform-driven partnerships in the life sciences sector and positions Alloy to continue pursuing innovative treatments with the potential to benefit patients.

More information about this collaboration can be found here.

The Polsinelli team included Christopher P. Simpson and Izzy C. Drake.